Follow-up study of hepatitis C virus infection in uremic patients on maintenance hemodialysis for 30 months

Table 1 Comparison of detection of HCVM in GI and GII

Parameter	GI (%) (n = 43)	GII (%) (n = 19)	P value
anti-HCVIgM (+)	21 (48.8)	6 (31.6)	> 0.05
anti-HCVIgG (+)	25 (58.1)	4 (21.1)	< 0.05
HCV RNA (+)	27 (62.8)	7 (36.8)	> 0.05
All three (+)	18 (41.9)	4 (21.1)	> 0.05
At least one (+)	29 (67.4)	8 (42.2)	> 0.05

Table 2 Comparison of clinical manifestation in HCV positive and negative group of HD patients

Clinical manifestation	HCVM positive group (n = 37)	HCVM negative group (n = 25)	P value
M/F	22/15	16/9	> 0.05
Mean age (years)	49.6 ± 16.8	48.4 ± 14.4	> 0.05
Range	16-71	26-67
Mean duration of HD (months)	31.2 ± 8.6	8.1 ± 4.7	< 0.01
Range	2-96	1-24
History of transfusion	29 (78.4%)	11 (44.0%)	< 0.01
EPO	12 (32.4%)	8 (32.0%)	> 0.05
History of kidney transplantation (n = 6)	6 (16.2%)	0 (0.0%)	< 0.05
History of CAPD (n = 8)	6 (16.2%)	2 (8.0%)	> 0.05
HBVM positive	18 (48.6%)	10 (40.0%)	< 0.01
ALT abnormality	10 (27.0%)	1 (4.0%)	< 0.01
BUN (mmol/L)	24.6 ± 8.6	28.4 ± 10.2	> 0.05
Cr (μmol/L)	1154.4 ± 402.6	1164.8 ± 468.5	> 0.05

Table 3 Relationship between dialysis times and HCV markers

HD time (Year)	n	IgM		IgG		HCV RNA		Only one marker positive
		n	%	n	%	n	%	n	%
< 1	32	9	28.1	8	25.0	12	37.5	14	43.8
1-2	18	9	50.0	10	55.6	11	61.1	12	66.7
2-3	5	3	60.0	4	80.0	4	80.0	4	80.0
> 3	7	6	85.7	7	100.0	7	100.0	7	100.0

Table 4 Relationship between number of transfusion and HCV markers

Transfusion (U)	n	IgM		IgG		HCV RNA		Only one marker positive
		n	%	n	%	n	%	n	%
0	22	6	27.3	7	31.8	6	27.3	8	36.4
1-5	8	2	25.0	2	25.0	4	50.0	4	50.0
6-10	16	7	43.8	6	37.5	10	62.5	11	68.8
11-20	6	4	66.7	5	83.3	5	83.3	5	83.3
> 30	10	8	80.0	9	90.0	9	90.0	9	90.0

Table 5 Comparison the clinical manifestation between HCVM positive and negative group in 22 patients without transfusion

Clinical manifestation	Positive group	Negative group	P value
Cases	8	14
M/F	5/3	8/6	> 0.05
Mean age (Years)	53.1 ± 14.2	49.6 ± 12.5	> 0.05
Range	30-71	30-67
Mean duration of HD (months)	24.2 ± 6.4	3.4 ± 1.6	< 0.01
Range	4-36	1-6
History of kidney transplantation	0	0
History of CAPD	0	0
EPO	3	5	> 0.05
ALT abnormality	3	0	< 0.01
BUN (mmol/L)	25.7 ± 7.8	26.4 ± 6.8	> 0.05
Cr (μmol/L)	1132.6 ± 482.6	1182.4 ± 464.3	> 0.05

Table 6 Positive prevalence of anti-HCV antibodies in six consecutive periods of 6 mo

Time	Cases	Positive (%)	Negative (%)
1995.6	63	37 (58.7)	26 (41.3)
1995.12	67	36 (53.7)	31 (46.3)
1996.6	62	34 (54.8)	28 (45.2)
1996.12	64	32 (50.0)	32 (50.0)
1997.6	76	40 (52.6)	36 (47.4)
1997.12	83	44 (53.0)	39 (47.0)

Table 7 Positive prevalence of anti-HCV antibodies in uremic patients when they were admitted to our HD center

Time	New patient	Positive (%)	Negative (%)
1995.6-1995.11	42	2 (4.8)	40 (95.2)
1995.12-1996.5	39	1 (2.6)	38 (97.4)
1996.6-1996.11	45	3 (6.7)	42 (93.3)
1996.12-1997.5	65	3 (4.6)	62 (95.4)
1997.6-1997.11	71	2 (2.8)	20 (97.2)
1997.12	21	0 (0.0)	21 (100.0)
Total	283?	11 (3.9)	273 (96.1)